Vera Ghali: Mitapivat Opens a New Chapter in Thalassemia Treatment
Vera Ghali, Member of the Lebanese Order of Physicians and Lebanese Pediatric Society, shared The Lancet‘s post on X, adding:
“A global, double-blind randomized ENERGIZE-T trial, conducted across 19 countries in North and South America, Europe, Asia-Pacific, and the Middle East, found that the orally administered drug, mitapivat, showed efficacy and well-tolerated adverse events (AE) in patients with transfusion-dependent alpha- and beta- thalassemia (TDT) who are more than 18 years.
Mitapivat is an oral allosteric pyruvate kinase (PK) activator that causes an increase in ATP production, reduces oxidative damage, and helps RBCs live longer.
It is to be administered as 100mg dose taken twice daily.
It is the first oral disease-modifying therapy for adults with TDT alpha-and beta- thalassemia that significantly reduced the transfusion burden for these patients and the associated risks and provides new treatment options.
However, patients taking mitapivat must be followed-up monthly for liver enzyme elevations due to risks of hepatotoxicity, and it is contraindicated in patients with liver cirrhosis and other liver diseases.
Liver toxicities are reversible upon discontinuation of mitapivat.”
The Lancet shared a post on X about a recent article by Maria Domenica Cappellini et al., adding:
“A new study assessed the efficacy and safety of mitapivat in adults with transfusion-dependent thalassaemia.
The study found that mitapivat significantly reduced the transfusion burden and was generally well tolerated, showing a favourable benefit–risk profile.”
Title: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors: Maria Domenica Cappellini, Sujit Sheth, Ali Taher, Hanny Al-Samkari, Ali Bülent Antmen, David Beneitez
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 3, 2026, 15:10Lady Joan Branson’s Story – The Hidden Danger of Hospitalization
-
Nov 3, 2026, 14:38Emna Hammami: Exploring the Haemophilia Treatment Landscape at the EHC New Technologies Conference
-
Nov 3, 2026, 14:20EHC Marks the Final Edition of Its New Technologies Conference in Bucharest
-
Nov 3, 2026, 14:15Rhiannon Morris: Awarded CASS Foundation Travel Grant to Present Research at ASH 2026
-
Nov 3, 2026, 14:14Edward Barnard: New Study Identifies an Association Between O Negative Blood Group and Trauma Mortality
-
Nov 3, 2026, 14:05Paula Escarcena Fernández: Selective Genicular Artery Embolization for Complex Regional Pain Syndrome of the Knee
-
Nov 3, 2026, 13:55Heiko Tschauner: New NOM-253 Standard Sets Higher Requirements for Blood Services in Mexico
-
Nov 3, 2026, 13:51The Future of Coagulation Diagnostics From Laboratory Testing to Better Patient Care
-
Nov 3, 2026, 13:45Keiyona Coots: Patient Blood Management as a Cornerstone of Safer Healthcare